If weight loss is a major concern for you, you should read this article to learn about the new upcoming weight loss medications in 2025 that will help you lose weight without any difficulties. These medications not only help you lose weight, but they also offer some other health benefits. Learn about new weight loss drugs in 2025 and how they can outperform the current weight loss medications (Ozempic and Semaglutide). Log on to https://doralhw.org/specialties/bariatric/ know more about weight loss.
New weight loss drugs in 2025
With advancements in medical science, new weight loss drugs emerge frequently. The most popular ones are:
- Retatrutide:
This medication is studied for weight loss and type 2 diabetes in adults. It works by attacking GLP-1, GIP, and glucagon receptor proteins in the body. Early trials have shown promising results, with participants losing up to 24% of their weight after 11 months of use. This shows more effectiveness than Zepbound for weight loss.
Research from Virginia Commonwealth University suggests that retatrutide can lower liver fat levels because in their phase 2 trial, they found that more than 85% of people who get retatrutide for 48 weeks (about 11 months) remove their metabolic dysfunction-associated steatotic liver disease (MASLD), a condition that can occur from obesity that can lead to liver scarring or other health issues.
Currently, it is the phase 3 trial process, which will get FDA approval in early 2026, if the data comes back positive. If the drug meets expectations, it will perform better than the effects of Wegovy and Mounjaro.
- CagriSema:
This is a combination treatment which involves cagrilinitide and semaglutide that mimic proteins such as amylin and GLP-1. Trials show excellent efficacy with good tolerability, similar to semaglutide. It’s phase 3 of the weight loss study, started in November 2022, and will be completed in October 2026.
Phase 2 study shows that CagriSema leads to more weight loss than cagrilintide and semaglutide by themselves; the adults who received CagriSema weekly for 7 months lost an average of 15% of their body weight. If this medication gets approved, it will become an effective alternative to Wegovy, as it requires fewer doses, and delivers quicker results.
- Orforglipron:
This medication is an oral GLP-1 receptor agonist, which is made of chemicals, not peptides. Unlike other injectable medications, it is commonly available in pill form, which is more convenient for some patients. Currently, phase 3 study is underway for chronic weight management in adults. This trial process started in June 2023 and is set to run until mid-2027.
During the phase 2 trial of orforglipron, it was found to help people lose body weight up to 15% after 8 months of use. It also offers some heart-related benefits. Trials show that it is easy to produce in bulk compared to Wegovy, with fewer gastrointestinal side effects. Additionally, as a first true oral alternative, it will be easily available and a more affordable weight loss choice.
- Maritide:
Maritide is short for maridebart cafraglutide, which is a long-acting injectable medication that mimics GLP-1 but blocks GIP. It is a good option for patients who value convenience and minimal disruption. This medication is currently on a phase 2 clinical trial and will proceed to a phase 3 trial soon.
In the phase 1 study, 3 doses of MariTide helped people to lose up to nearly 15% of their body weight after 3 months of use. It may help people to maintain their results over time, too. People are able to maintain their results for 5 months after their last dose. These solid results make this one worth watching closely until it is approved by the FDA.
- GSBR-1290:
While still in development, GSBR-1290 is another oral GLP-1 antagonist used to manage chronic obesity and type 2 diabetes compared to Orforglipron. It is a daily pill and available in both capsule and tablet form. Its unique compound design makes it safer and ensures more consistent absorption.
Studies found that it helps participants lose more than 6% of body weight after 12 weeks (about 3 months) of use compared to placebo. If its trial is successful, it would create a new submarket for oral GLP-1s, a highly attractive option in a private pharmacy setting.
These new weight loss drugs in 2025 look promising and are good alternatives to Ozempic and semaglutide in terms of dosage, side effects, and long-lasting effects. This shows a better future for the weight loss medication market with better health outcomes.
Need help with weight loss? Visit our bariatric specialists in the Brooklyn clinic for professional medical support. Call us to book your appointment now!!!! If you’re ready to take the next step in managing your weight, we recommend consulting with our Bariatric experts to explore the right treatments or therapies for you. Always listen to your body and adjust your daily routine to prioritize your well-being. If you are looking for a weight loss surgery center near you, contact us on +1 718 367 2555 for a consultation with our bariatric doctors. Want to learn more about types of bariatric surgery like Gastric sleeve surgery, Laparoscopic surgery, Gastric bypass surgery, Sleeve gastrectomy, or LAP band surgery? Doral Health and Wellness has one of the best bariatric doctors and surgeons to treat obesity and weight problems. Book your appointment and walk in at 1797 Pitkin Avenue, Brooklyn, New York 11212.
